We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
PolyPeptide customer Cara Therapeutics with FDA approval for novel treatment of moderate-to-severe pruritus in hemodialysis patients
1 Sep 2021 - Long-term collaborative development process for peptide API successfully completed and continued with commercial supply agreement PolyPeptide is pleased to announce that its customer Cara Therapeutics (Nasdaq: […]
Read morePolyPeptide reports strong H1 2021 revenue growth and operating leverage amidst favorable market environment and encouraging business trends
17 Aug 2021 - PolyPeptide Group AG (SIX: PPGN), a global leader in peptide custom development and manufacturing, today announced its results for the first half of 2021: – Revenue […]
Read moreCircular Aqueous Fmoc/t-Bu Solid-Phase Peptide Synthesis
16 Jul 2021 - Circular economy and aqueous synthesis are attractive concepts for sustainable chemistry. Here it is reported that the two can be combined in the universal method for peptide chemistry, fluorenylmethoxycarbonyl(Fmoc)/t-Bu solid-phase peptide synthesis (SPPS). […]
Read morePolyPeptide Group appoints Christina Del Vecchio as General Counsel and member of the Executive Committee
25 Jun 2021 - PolyPeptide Group AG, a global leader in peptide development and manufacturing, today announced the appointment of Christina Del Vecchio as General Counsel and member of the […]
Read moreProclamation honoring Jane Salik upon her retirement
11 May 2021 - The city of Torrance, California, honored Jane Salik for her investment in the Torrance community and her outstanding contributions to the Science and Peptide Industry. 05-11-21 […]
Read morePolyPeptide Group announces the exercise of the full over-allotment option
5 May 2021 - PolyPeptide Group AG ("PolyPeptide" or "the Group"), a global leader in peptide development and manufacturing, today announced that the Joint Global Coordinators have exercised in full the over-allotment option granted in connection with its Initial Public Offering (the "IPO") at the offer price of CHF 64 per share.
Read moreStock exchange listing
29 Apr 2021 - Today the PolyPeptide Group became a public company. Our shares are being traded on SIX, the Swiss Stock Exchange. What an exhilarating day! Today the PolyPeptide […]
Read moreDownstream Processes for peptide manufacturing: Optimization strategy and latest technical trends
2 Apr 2021 - This article highlights the key steps in the development and implementation of a proper purification strategy for the manufacture of peptide APIs. Our ambition is to recommend a structured methodology, including a good understanding of the separation mechanism to develop the process and to apply the latest technologies for the optimization of the purification step to reach the best performance of the manufacturing process. […]
Read moreGreen Chemistry Articles of Interest to the Pharmaceutical Industry
11 Mar 2021 - Dalton, C.; Diorazio, L. J.; Doerfler, J.; Engl, O. D.; Han, Z. S.; Howell, G. P.; Latham, J.; Li, W.; McLaws, M.; Munday, R. H.; Navarro, […]
Read more